In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 1, 2000, Pages 137-140

  Molina, Judith ^a,b   Brener, Zigman ^b   Romanha, Alvaro J ^b   Urbina, Julio A ^c  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; BENZNIDAZOLE; NITROFURANTOIN; NITROIMIDAZOLE; ANTITRYPANOSOMAL AGENT; TRIAZOLE DERIVATIVE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; DEATH; DRUG ACTIVITY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; TRYPANOSOMA CRUZI; ANIMAL; DRUG EFFECT; PARASITOLOGY;

ANIMALS; CHAGAS DISEASE; DRUG RESISTANCE; FEMALE; MICE; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 0033926933     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.1.137     Document Type: Article

References (10)

1. World Health Organization. (1995). Tropical Disease Research, Twelfth Programme Report. WHO, Geneva, 129-33.
2. Rassi, A. & Luquetti, A. O. (1992). Therapy of Chagas Disease. In Chagas Disease (American Trypanosomiasis): Its Impact on Transfusion and Clinical Medicine, (Wendel, S., Brener, Z., Camargo, M. E. & Rassi, A., Eds), pp. 237-47. ISBT BRAZIL'92, São Paulo, Brazil.
3. Añez, N., Carrasco, H., Parada, H., Crisante, G., Rojas, A., Fuenmayor, C. et al. (1999). Myocardial parasite persistence in chronic chagasic patients. American Journal of Tropical Medicine and Hygiene 60, 726-32.
4. Kirchhoff, L. V. (1999). Chagas' Disease (American trypanosomiasis): a tropical disease now emerging in the United States. In Emerging Infections-3, (Scheld, W. M., Craig, W. A. & Hughes, J. M., Eds), pp. 111-34. American Society for Microbiology, Washington, DC.
5. Urbina, J. A. (1999). Chemotherapy of Chagas' disease: the how and the why. Journal of Molecular Medicine 77, 332-8.
6. Urbina, J. A., Payares, G., Molina, J., Sanoja, C., Liendo, A., Lazardi, K. et al. (1996). Cure of short- and long-term experimental Chagas disease using D0870. Science 273, 969-71.
7. Urbina, J. A., Payares, G., Contreras, L. M., Liendo, A., Sanoja, C., Molina, J. et al. (1998). Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy 42, 1771-7.
8. Filardi, L. S. & Brener, Z. (1987). Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 755-9.
9. Martins-Filho, O. A., Pereira, M. E., Carvalho, J. F. S., Cançado, J. R. & Brener, Z. (1995). Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clinical and Diagnostic Laboratory Immunology 2, 569-73.
10. Molina, J., Martins-Filho, O., Brener, Z., Romanha, A. J., Loebenberg, D. & Urbina, J. A. (2000). Activity of the triazole derivative SCH 56592 (Posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrobial Agents and Chemotherapy 44, 150-5.